<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808830</url>
  </required_header>
  <id_info>
    <org_study_id>bakircaymzeren02</org_study_id>
    <nct_id>NCT04808830</nct_id>
  </id_info>
  <brief_title>Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension</brief_title>
  <official_title>Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Izmir Bakircay University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istanbul University-Cerrahpasa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Izmir Bakircay University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevalence of musculoskeletal pain and its impact of quality of life and functional exercise&#xD;
      capacity will be evaluated in patients with pulmonary arterial hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although main symptoms of pulmonary arterial hypertension (PAH) include shortness of breath&#xD;
      and exercise intolerance, patients may also experience symptoms related to musculoskeletal&#xD;
      system such as muscle fatigue or pain. Due to insufficient cardiac output and chronic&#xD;
      arterial hypoxemia, oxygen cannot be delivered to skeletal muscles sufficiently, especially&#xD;
      during exertion. In addition, inflammation, which is thought to play an important role in&#xD;
      pulmonary vascular remodeling and disease pathophysiology in these patients, affects skeletal&#xD;
      muscles as well. Increased sympathetic tone in PAH restricts the perfusion of skeletal muscle&#xD;
      by increasing peripheral vascular resistance. With the addition of physical inactivity to all&#xD;
      these factors, skeletal muscle metabolism is further impaired. Furthermore, drugs used for&#xD;
      the treatment of PAH may induce musculoskeletal pain as a side effect. Musculoskeletal pain&#xD;
      is one of the most important factors impairing individual's quality of life, regardless of&#xD;
      whether there is an underlying disease. Our aim in this study is to evaluate pain prevalence&#xD;
      in the musculoskeletal system over 9 body regions, to compare the pain prevalence of patients&#xD;
      using different types of PAH drugs and to examine impact of musculoskeletal pain on quality&#xD;
      of life and functional capacity in patients with PAH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Actual">June 15, 2021</completion_date>
  <primary_completion_date type="Actual">June 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Nordic Musculoskeletal Questionnaire</measure>
    <time_frame>At baseline</time_frame>
    <description>The Nordic Musculoskeletal Questionnaire will be used to evaluate musculoskeletal pain prevalence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The EmPHasis-10 questionnaire</measure>
    <time_frame>At baseline</time_frame>
    <description>The EmPHasis-10 questionnaire will be used to measure quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Minnesota Living with Heart Failure Questionnaire</measure>
    <time_frame>At baseline</time_frame>
    <description>The Minnesota Living with Heart Failure Questionnaire will be used to measure quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-min walk distance</measure>
    <time_frame>At baseline</time_frame>
    <description>Distance walked in six minutes will be recorded. Test will be conducted according to the guideline of American Thoracic Society (ATS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire - Short Form</measure>
    <time_frame>At baseline.</time_frame>
    <description>International Physical Activity Questionnaire - Short Form will be used to measure physical activity level</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">61</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Pulmonary arterial hypertension</arm_group_label>
    <description>Adult patients with pulmonary arterial hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of musculoskeletal pain prevalence</intervention_name>
    <description>Prevalence of musculoskeletal pain will be evaluated over 9 body regions using The Nordic Musculoskeletal Questionnaire.</description>
    <arm_group_label>Pulmonary arterial hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of quality of life</intervention_name>
    <description>Quality of life will be evaluated using The EmPHasis-10 questionnaire and The Minnesota Living with Heart Failure Questionnaire.</description>
    <arm_group_label>Pulmonary arterial hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of functional exercise capacity</intervention_name>
    <description>Functional exercise capacity will be evaluated using 6-min walk test.</description>
    <arm_group_label>Pulmonary arterial hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of physical activity level</intervention_name>
    <description>Physical activity level will be evaluated using International Physical Activity Questionnaire- Short Form</description>
    <arm_group_label>Pulmonary arterial hypertension</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients diagnosed with pulmonary arterial hypertension&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of pulmonary arterial hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of heart failure or any chronic respiratory disease&#xD;
&#xD;
          -  Recent coronary bypass surgery&#xD;
&#xD;
          -  Recent acute myocardial infarction&#xD;
&#xD;
          -  Having a pacemaker&#xD;
&#xD;
          -  Having any orthopedic or neurologic diseases which may impede walking or exercising&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Istanbul University-Cerrahpasa, Institute of Cardiology</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Izmir Bakircay University</investigator_affiliation>
    <investigator_full_name>Melih Zeren</investigator_full_name>
    <investigator_title>Assist. Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

